ClinicalTrials.gg
Active, not recruitingNCT06496620ZIONUpdated Oct 28, 2026

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

A Phase 2 interventional study of Biological: Solrikitug low dose and Biological: Solrikitug high dose in COPD, sponsored by Uniquity One (UNI). Active, not recruiting at 110 sites in 4 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Uniquity One (UNI) · Phase 2, Interventional, and Treatment

How we know

Updated Oct 28, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 139 open to participants now, 174 under way, 21 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Enrollment
404th of 1,039
182 · median 100
Started
2024
with 39 others
Phase 2
193 of 1,280
16 open now
Primary completion
2026-09
later than 35 of 173 live
Registered
1,177th of 1,280
by date

Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 404th largest by enrollment of the 1,039 interventional ones that give a count, is one of 40 that started in 2024, is one of 193 in phase 2, reaches primary completion later than 35 of the 173 other live ones, and was the 1,177th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

139 of the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).

Read the detailed description

This is a 12-week randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of 2 dose levels of solrikitug versus placebo on top of standard of care in participants with COPD.

Approximately 171 eligible participants with COPD will be randomized at approximately 60-90 sites. Participants will receive solrikitug, or placebo, administered via subcutaneous injection at the study site, over a 12-week treatment period. The study also includes a post-treatment follow-up period of 16 weeks.

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 40 years of age and no older than 75 years.
  • Documented diagnosis of for at least 12 months prior to Screening, defined by the GOLD Guidelines (2023), and elevated blood eosinophils at screening.
  • At Screening /FVC ratio must be \<0.70, and Post-bronchodilator FEV1 must be ≥40% to \<80% predicted normal value calculated using Global Lung Function Initiative (GLI) reference equations (Cooper et al 2017).
  • Symptomatic (COPD Assessment Test [CAT] Score ≥10) at Screening Visit 1.
  • Participants must be on 2 or more inhaled maintenance medications for management of their COPD, for at least 3 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Female participant who is pregnant or breastfeeding.
  • Participant has a known to any component of the formulation of solrikitug, including any of the , or a history of anaphylactic reaction to any therapeutic monoclonal antibody.
  • Participant has history or evidence of any cardiovascular, hematologic, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, renal and/or other major disease or , or any other condition that in the opinion of the Investigator or Medical Monitor might obfuscate the study data.
  • Any other pulmonary disease than that in the opinion of the Investigator, the severity of the disorder would impact the conduct of the study.
  • Undergone major lung surgery, within 1 year of Screening Visit 1.
  • Participant has a lower respiratory tract infection that required antibiotics within 6 weeks prior to Screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    Biological: Solrikitug High Dose

    Solrikitug

    Biological: Biological: Solrikitug high dose

  • Other
    Placebo

    Placebo

    Other: Placebo

  • Experimental
    Biological: Solrikitug Low Dose

    Solrikitug

    Biological: Biological: Solrikitug low dose

Interventions

  • BiologicalBiological: Solrikitug low dose

    Solrikitug subcutaneous injection

  • BiologicalBiological: Solrikitug high dose

    Solrikitug subcutaneous injection

  • OtherPlacebo

    Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Change from baseline in blood eosinophil counts

    To assess the effect of multiple doses of solrikitug on blood eosinophil counts compared with placebo

    Time frame: Through week 12

Secondary outcomes

  1. Change from baseline in FEV1 Adverse events (AEs) and serious adverse events (SAEs)

    To assess the safety and tolerability of multiple doses of solrikitug

    Time frame: Through week 12 To week 28

07

Study locations

110 sites

Showing the first 100 of 110 sites across 4 countries. Choose a country and city above to see the rest.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Sep 2026, 25 months.

Of 120 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 25 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 11, 2024
StartActual
Aug 14, 2024
Primary completionActual
Sep 23, 2026
CompletionEst.
Feb 1, 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Sep 23, 2026 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Primary completion Sep 30, 2026→Sep 23, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06496620
Lead sponsor
Uniquity One (UNI)
Collaborators
DevPro Biopharma
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
Aug 14, 2024
Primary completion
Sep 23, 2026
Completion
Feb 1, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Andrew W Lee, MD
study director · Vice President, Clinical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion